AL amyloidosis melphalan and dexamethasone oral |
Medium Cycle 1. Low Cycle 2 onwards if patient tolerates |
March 2022 |
Multiple myeloma and AL amyloidosis CTD (CYCLOPHOSPHamide thalidomide dexamethasone) oral |
Low |
February 2023 |
Multiple myeloma carfilzomib and dexamethasone twice weekly |
High cycle 1, Medium cycle 2 onwards if patient tolerates |
February 2024 |
Multiple myeloma carfilzomib and dexamethasone weekly |
High cycle 1, Medium cycle 2 onwards if patient tolerates |
February 2024 |
Multiple myeloma CyBorD (CYCLOPHOSPHamide bortezomib dexamethasone) twice weekly |
Low |
August 2023 |
Multiple myeloma CyBorD (CYCLOPHOSPHamide bortezomib dexamethasone) weekly |
Low |
August 2023 |
Multiple myeloma daratumumab |
High cycle 1, Medium cycle 2 onwards if patient tolerates |
August 2024 |
Multiple myeloma daratumumab maintenance |
High cycle 1, Medium cycle 2 onwards if patient tolerates |
August 2023 |
Multiple Myeloma daratumumab SUBCUT
- SAHCDC Approved non-eviQ protocol Multiple Myeloma daratumumab SUBCUT (PDF 2.3MB) |
Low, Confirm nursing/pharmacy manufacturing availability for Regional LHN sites |
December 2024 |
Multiple Myeloma daratumumab SUBCUT bortezomib dexamethasone
- SAHCDC Approved non-eviQ protocol Multiple Myeloma daratumumab SUBCUT bortezomib dexamethasone (PDF 3.3MB) |
Low, Confirm nursing/pharmacy manufacturing availability for Regional LHN sites |
December 2024 |
Multiple myeloma DRd (daratumumab lenalidomide dexamethasone) |
High cycle 1, Medium cycle 2 onwards if patient tolerates |
August 2023 |
Multiple myeloma DT-PACE (dexamethasone thalidomide cISplatin DOXOrubicin CYCLOPHOSPHamide etoposide) |
High |
August 2024 |
Multiple myeloma DVd (daratumumab bortezomib dexamethasone) treatment overview The SAHCDC has endorsed the use of weekly dosing of Bortezomib (Day 1, 8 and 15) for patients unable/unlikely to tolerate twice weekly dosing |
High cycle 1, Medium cycle 2 onwards if patient tolerates |
August 2023 |
Multiple myeloma D-VMP (daratumumab bortezomib melphalan prednisolone) |
High cycle 1, Medium cycle 2 onwards if patient tolerates |
August 2023 |
Multiple Myeloma elotuzumab
lenalidomide dexamethasone — interim Multiple Myeloma elotuzumab lenalidomide dexamethasone protocol (PDF 431KB)
|
Medium |
December 2023 |
Multiple myeloma ixazomib lenalidomide and dexamethasone oral |
Low |
February 2024 |
Multiple myeloma lenalidomide and dexamethasone oral |
Low |
February 2024 |
Multiple myeloma lenalidomide maintenance post autologous transplant |
Low |
August 2023 |
Multiple myeloma MPB (melphalan prednisolone bortezomib) |
Medium cycle 1, Low cycle 2 on if patient tolerates |
August 2024 |
Multiple myeloma MPT (melphalan prednisolone thalidomide) oral |
Low |
August 2023 |
Multiple myeloma pomalidomide and dexamethasone oral The SAHCDC has endorsed the use of weekly dosing of Bortezomib (Day 1, 8 and 15) for patients unable/unlikely to tolerate twice weekly dosing |
Low |
February 2023 |
Multiple myeloma PVd (pomalidomide bortezomib and dexamethasone)3 |
Low |
August 2023 |
Multiple myeloma RVd (lenalidomide bortezomib dexamethasone) PETHEMA overview |
Low |
February 2023 |
Multiple myeloma induction RVd (lenalidomide bortezomib dexamethasone) PETHEMA |
Low |
February 2023 |
Multiple myeloma consolidation RVd (lenalidomide bortezomib dexamethasone) PETHEMA |
Low |
February 2023 |
Multiple myeloma RVd (lenalidomide bortezomib dexamethasone) SWOG S0777 overview |
Low |
February 2023 |
Multiple myeloma induction RVd (lenalidomide bortezomib dexamethasone) SWOG S0777 |
Low |
February 2023 |
Multiple myeloma RVd-lite (lenalidomide bortezomib dexamethasone) overview |
Low |
February 2023 |
Multiple myeloma induction RVd-lite (lenalidomide bortezomib dexamethasone) |
Low |
February 2023 |
Multiple myeloma consolidation RVd-lite lenalidomide and bortezomib |
Low |
February 2023 |
Multiple myeloma maintenance RVd-lite lenalidomide |
Low |
February 2023 |
Multiple myeloma thalidomide and dexamethasone oral |
Low |
February 2023 |